Table 2 Peripheral blood lymphocyte quantification
CD4:CD8 ratio | CD3CD4 (%) | CD3CD4 106cells/L | CD3CD8 (%) | CD3CD8 106cells/L | CD16CD56 (%) | CD16CD56 106cells/L | |
|---|---|---|---|---|---|---|---|
no-fatigue controls (n = 32) | 2.43 (0.97) | 51.1 (8.2) | 990 (376) | 22.9 (5.5) | 440 (198) | 11.7 (6.7) | 210 (99) |
PI-CFS/ICF (n=24) | 2.05 (0.76) | 50.5 (7.0) | 939 (366) | 27.0 (7.0) | 497 (207) | 7.5 (3.5)** | 130 (54)** |
PI-CFS (n = 19) | 2.01 (0.77) | 50.3 (6.9) | 912 (296) | 27.5 (7.0)* | 497 (200) | 8.0 (3.6)* | 138 (55)** |
Fatigue other cause (n=12) | 2.37 (1.14) | 51.9 (8.1) | 1132 (543) | 26.1 (10.4) | 635 (531) | 8.7 (4.6) | 186 (139) |
Fatigue recovered (n=12) | 1.80 (0.82)* | 46.1 (10.3) | 834 (318) | 28.8 (9.1)* | 545 (225) | 10.6 (9.0) | 203 (188) |
no-FGID (n=26) | 2.74 (1.06) | 53.3 (8.6) | 1008 (363) | 21.1 (5.4) | 394 (167) | 11.3 (7.1) | 192 (80) |
All FGID (n=54) | 1.96 (0.75)** | 48.9 (7.7)* | 958 (415) | 27.6 (7.6)*** | 555 (311)** | 9.1 (5.6) | 176 (129) |
PI-FGID (n=45) | 2.00 (0.78)** | 49.2 (7.9)* | 949 (418) | 27.1 (7.35)** | 537 (313)* | 8.8 (5.4) | 169 (122) |
PI-IBS (n=23) | 1.97 (0.91)** | 49.5 (8.8) | 988 (463) | 28.2 (7.1)** | 592 (376)* | 8.1 (5.0)* | 157 (111) |
no-FGID/no-fatigue controls (n=23) | 2.65 (1.05) | 52.4 (8.8) | 974 (380) | 21.5 (5.5) | 389 (171) | 11.8 (7.6) | 194 (86) |
FGID&CFS/ICF(n=23) | 2.01 (0.75)* | 50.2 (7.0) | 923 (366) | 27.3 (6.9)** | 500 (211) | 7.4 (3.5)** | 127 (53)* |
FGID, no fatigue (n=21) | 1.82 (0.65)** | 46.9 (8.5)* | 924 (356) | 27.9 (7.3)** | 548 (214)** | 11.0 (7.0) | 223 (156) |
Fatigue other cause w/wo FGID (n=12) | 2.37 (1.14) | 51.9 (8.1) | 1133 (543) | 26.1 (10.4) | 635 (531) | 8.7 (4.6) | 186 (140) |